Stock Analysis

CStone Pharmaceuticals Full Year 2022 Earnings: Revenues Beat Expectations, EPS Lags

Published
SEHK:2616
Source: Shutterstock

CStone Pharmaceuticals (HKG:2616) Full Year 2022 Results

Key Financial Results

  • Revenue: CN¥481.4m (up 98% from FY 2021).
  • Net loss: CN¥902.7m (loss narrowed by 53% from FY 2021).
  • CN¥0.77 loss per share (improved from CN¥1.65 loss in FY 2021).
earnings-and-revenue-growth
SEHK:2616 Earnings and Revenue Growth April 27th 2023

All figures shown in the chart above are for the trailing 12 month (TTM) period

CStone Pharmaceuticals Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 2.8%. Earnings per share (EPS) missed analyst estimates by 4.1%.

Looking ahead, revenue is forecast to grow 37% p.a. on average during the next 3 years, compared to a 35% growth forecast for the Biotechs industry in Hong Kong.

Performance of the Hong Kong Biotechs industry.

The company's shares are down 4.8% from a week ago.

Risk Analysis

You still need to take note of risks, for example - CStone Pharmaceuticals has 2 warning signs we think you should be aware of.

Valuation is complex, but we're helping make it simple.

Find out whether CStone Pharmaceuticals is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.

View the Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.